M Ventures invests in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.
Business Model:
Revenue: $0
Employees: 0-0
Address: Gustav Mahlerplein 102 Toyo lto Building
City: Amsterdam
State: noord-holland
Zip: 1082 MA
Country: NL
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2020 | Xilio Therapeutics | Series B | 100.5M |
9/2016 | IOmx Therapeutics | Series A | 44.6M |
10/2021 | IOmx Therapeutics | Series B | 0 |
7/2016 | Progyny | Series B | 14.7M |
2/2021 | Medisafe | Series C | 0 |
6/2023 | Astraveus | Seed Round | 0 |
5/2018 | Akili Interactive Labs | Series C | 0 |
5/2021 | Akili Interactive Labs | Series D | 0 |
2/2022 | Plexium | Series B | 0 |
10/2022 | Metalenz | Series B | 0 |
1/2023 | Rewind Therapeutics | Series B | - |
5/2019 | Altoida | Series A | 6.3M |
11/2015 | ObsEva | Series B | 58.9M |
11/2019 | ResoTher Pharma | Seed Round | 2.4M |
4/2021 | Anavo Therapeutics | Seed Round | 0 |
2/2018 | FanAI | Seed Round | 2.5M |
12/2022 | Sonde Health | Series B | 19.3M |
5/2022 | PictorLabs | Series A | 0 |
9/2020 | Mosa Meat | Series B | 0 |
8/2017 | Alcan Systems | Series A | 8.8M |
5/2021 | MemryX | Series A | - |
9/2015 | Asceneuron | Series A | 30.8M |
2/2023 | UNISERS | Seed Round | 14M |
4/2014 | Padlock Therapeutics | Series A | 14.7M |
3/2013 | Calypso Biotech | Seed Round | 3.3M |
6/2017 | iOnctura | Seed Round | - |
4/2009 | Ambrx | Series D | 10M |
2/2019 | Calypso Biotech | Series A | 22.7M |
9/2021 | Calypso Biotech | Series A | 0 |
6/2009 | Anaphore | Series A | 13M |
1/2022 | Future Fertility | Series A | - |
10/2017 | Peratech | Equity | 12.4M |
3/2014 | Bird Rock Bio | Series B | 0 |
4/2019 | Sonde Health | Series A | 0 |
1/2020 | iOnctura | Series A | 16.6M |
2/2014 | Synaffix BV | Series A | - |
2/2021 | Metalenz | Series A | 10M |
1/2012 | Galecto | Seed Round | - |
4/2013 | Canbex Therapeutics | Venture Round | 3.2M |
6/2023 | Celestial AI | Series B | 100M |
9/2021 | Legendairy Foods | Series A | 0 |
11/2017 | Wiliot | Series A | 5M |
3/2017 | Medisafe | Series B | 0 |
8/2018 | ApoGen Biotechnologies | Series A | 4M |
1/2017 | ARTSaVIT | Series A | 6.3M |
9/2020 | NanoSyrinx | Pre Seed Round | - |
11/2021 | Biolinq | Series B | 0 |
7/2021 | Wiliot | Series C | 0 |
11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
7/2020 | iOnctura | Series A | 5.8M |
5/2018 | Gamelynx | Equity | 1.2M |
8/2021 | Immunitas Therapeutics | Series B | 0 |
1/2017 | Macrophage Pharma | Series A | 0 |
2/2017 | Prexton Therapeutics | Series B | 31.1M |
10/2018 | Galecto | Series C | 90.2M |
11/2021 | NeoLogic (VLSI) | Seed Round | 2.8M |
7/2021 | Artios Pharma | Series C | 0 |
8/2018 | Vantage Point | Pre Seed Round | 1.4M |
3/2022 | Concerto Biosciences | Equity | 24.5M |
6/2017 | Indi Molecular | Series A | 0 |
5/2020 | SynSense | Series A | - |
7/2019 | Forendo Pharma | Venture Round | 0 |
9/2016 | Artios Pharma | Series A | 0 |
5/2019 | Storm Therapeutics | Series A | 17.8M |
7/2021 | NanoSyrinx | Seed Round | 8.5M |
2/2018 | FanAI | Venture Round | 0 |
11/2018 | curbFlow | Seed Round | - |
7/2020 | DNA Script | Series B | 50M |
9/2017 | DNA Script | Series A | 13.2M |
8/2018 | Vantage Point | Pre Seed Round | 0 |
2/2015 | Prexton Therapeutics | Series A | 10M |
11/2020 | Ferroelectric Memory Company | Series B | 0 |
10/2013 | Galecto | Series B | 6.3M |
12/2022 | Storm Therapeutics | Series B | 30M |
1/2012 | Translate Bio | Series A | 20.7M |
10/2021 | DNA Script | Series C | 0 |
7/2016 | Akili Interactive Labs | Series B | 42.4M |
10/2017 | aveni | Series B | 10.5M |
2/2022 | Celestial AI | Series A | 56M |
7/2018 | Mosa Meat | Series A | 0 |
3/2022 | Concerto Biosciences | Series A | 24.5M |
12/2019 | Neurable | Series A | 6M |
11/2018 | Ribometrix | Series A | 30M |
7/2015 | Translate Bio | Series B | 0 |
4/2011 | F-Star Therapeutics | Venture Round | 0 |
6/2018 | Mighty Bear Games | Seed Round | 2.5M |
1/2021 | Theolytics | Series A | 6.8M |
10/2014 | Forendo Pharma | Series A | 0 |
6/2018 | Inthera Bioscience | Series A | 0 |
10/2022 | Nucleome Therapeutics | Series A | 42.3M |
9/2020 | Tipe | Seed Round | 2.1M |
3/2023 | PxE | Seed Round | 0 |
2/2022 | Micropsi Industries | Series B | 0 |
3/2019 | Biolinq | Series A | 4.8M |
11/2017 | Biolinq | Series A | 0 |
6/2020 | Micropsi Industries | Series A | - |
10/2013 | F-Star Therapeutics | Series A | 0 |
5/2009 | Bird Rock Bio | Series A | 13M |
1/2010 | F-Star Therapeutics | Series A | 11.5M |
5/2021 | Soteria Biotherapeutics | Series A | 42M |
4/2016 | Metabomed | Series A | 18M |
1/2018 | Rewind Therapeutics | Series A | 18.3M |
10/2014 | Raze Therapeutics | Series A | 24M |
1/2023 | Rewind Therapeutics | Series A | - |
2/2020 | Scipio Bioscience | Series A | 6.5M |
4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
6/2016 | Storm Therapeutics | Series A | 16M |
7/2019 | SIMULATE | Seed Round | 7M |
9/2020 | SeeQC | Series A | 22.4M |
3/2022 | Altoida | Series A | 0 |
9/2018 | Forendo Pharma | Venture Round | 0 |
5/2017 | Inthera Bioscience | Series A | 0 |
3/2022 | Altoida | Series A | 0 |
2/2022 | Plexium | Series B | 0 |
2/2022 | Micropsi Industries | Series B | 0 |
2/2022 | Celestial AI | Series A | 0 |
1/2022 | Future Fertility | Series A | - |
11/2021 | NeoLogic (VLSI) | Seed Round | 0 |
11/2021 | Biolinq | Series B | 0 |
10/2021 | DNA Script | Series C | 0 |
10/2021 | IOmx Therapeutics | Series B | 0 |
9/2021 | Legendairy Foods | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|